Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

Nanexa has signed a license and option agreement with Moderna covering development of up to five undisclosed compounds, under which Nanexa receives a $3 million upfront payment, is eligible for up to $500 million in development and commercial milestone payments and will earn a tiered single‑digit royalty on product sales. Moderna gets a license to use Nanexa’s PharmaShell® atomic layer deposition (ALD) drug‑delivery platform for an initial selected compound and holds options to license up to four additional compounds following preclinical evaluation, with each option triggering a pre‑negotiated license. The deal both validates PharmaShell’s potential to deliver tailored release profiles and improved stability for advanced biologics and creates meaningful upside for Nanexa if Moderna advances candidates toward commercialization.

Analysis

Nanexa announced a license and option agreement with Moderna dated December 10, 2025, granting Moderna a license to use Nanexa’s PharmaShell® platform for an initial selected compound and options to license up to four additional compounds. Nanexa receives a USD 3 million upfront payment, is eligible for up to USD 500 million in development and commercial milestone payments and will earn a tiered single-digit royalty on product sales if candidates progress to market.

PharmaShell® is based on atomic layer deposition (ALD) and is presented as enabling precise encapsulation, tailored release profiles, improved product stability and high drug load/low injection volume, which directly targets use cases in metabolic disease, oncology, cardiovascular and psychiatry cited by Nanexa. Moderna’s participation provides third-party validation of the platform and expands Nanexa’s partner roster alongside existing collaborators such as Novo Nordisk and AstraZeneca.

Financially, the deal provides immediate non-dilutive cash and a defined upside framework but the majority of value is contingent on preclinical success, option exercises and later-stage development; royalties are capped at tiered single-digit rates. Near-term market impact is moderately positive per sentiment metrics, but investors should treat milestone and royalty streams as contingent, long-dated and binary with development risk.

Key Decisions for Investors

• Consider a modest, size-constrained long exposure to Nanexa to capture partnership validation but limit position size given binary preclinical and option risks
• Track three near-term catalysts closely—Moderna’s selection of the initial compound, preclinical evaluation results and any exercise of the additional options—as these are the primary value inflection points
• Model revenue conservatively: recognize the USD 3 million upfront now but treat the up-to USD 500 million in milestones and single-digit royalties as contingent upside until contractual triggers occur
• For Moderna holders, treat this as a technical collaboration that could improve candidate delivery profiles; monitor disclosures for material candidate-level efficacy or stability improvements before adjusting MRNA exposure